United States: Pharmaceutical Companies Object To HHS Drug Pricing Disclosure Rule

Several parties from the pharmaceutical industry have teamed up with an advertising association to file a lawsuit against the Department of Health and Human Services (HHS) to prevent a new drug pricing disclosure rule from going into effect. The legal challenge was filed on June 14, 2019 and takes issue with a final rule adopted by HHS on May 8, 2019 (which we previously blogged about here). The rule purports to provide consumers with information regarding the price of prescription drugs. However, opponents of the final rule counter that the opposite will occur and that it will actually mislead patients about the price of prescription drugs. This point may not be difficult for the plaintiffs to demonstrate in support of their request for a declaratory judgment that the rule is unlawful, since even HHS has admitted in the final rule preamble that the new requirement may "discourage patients from using beneficial medications, reduce access, and potentially increase total cost of care."

According to the Complaint filed by Eli Lilly, Merck, Amgen, and the Association of National Advertisers, HHS relied upon an "unprecedentedly broad construction of the agency's statutory authority" to enact the final rule. The final rule requires direct-to-consumer pharmaceutical television advertisements to include specific, government-scripted statements highlighting what HHS describes as the "list price" of the advertised product. However, the Complaint points out that the "list price" is not – as regular people will undoubtedly infer from the overall context – a sales price for retail transactions like what may be seen in comparable advertisements for non-prescription drug products. Instead, the "list price" under the HHS rule is actually the "Wholesale Acquisition Cost," or "WAC," of the drug in question. The WAC is again not the suggested retail price for patients. As the Complaint explains, WAC is "expressly defined by federal statute as the price charged to wholesalers, before the application of discounts, rebates, and other adjustments that substantially reduce the net payment for the prescription drug." In other words, HHS is directing manufacturers to "advertise to consumers the price that manufacturers charge to wholesalers, even though these are two entirely different concepts." Furthermore, third-party payors, such as insurance plans and government health programs, generally cover the bulk of the costs of a branded prescription drug advertised on television, which means that patients are not paying anything close to the WAC of an advertised drug at the pharmacy or when purchasing the drug through a health care provider.

Accordingly, the plaintiffs argue that mandating the disclosure of the WAC in television advertisements will have the opposite impact than the one HHS claims that it intends to have and thus that this final rule will force pharmaceutical companies to explicitly mislead consumers about the price of prescription drugs. In addition, the Complaint sets forth the plaintiffs' arguments that the rule is unlawful for two primary reasons: (1) HHS has no authority to impose the final rule; and (2) the final rule violates the First Amendment.

HHS' Authority

Addressing the first argument, the Complaint outlines the historical development of direct-to-consumer drug advertising and explains that the Food and Drug Administration (FDA) requires that prescription drug advertisements "cannot be false or misleading with respect to side effects, contradictions, or effectiveness; must present a fair balance between the risks and benefits of the product; and must, depending on the medium in which the advertisement appears, either disclose all the risks in the product's approved labeling or make 'adequate provision' for disseminating the product's labeling to the audience." Violation of any one of those regulatory requirements for prescription drug advertisements can lead to criminal or civil penalties. However, FDA has long acknowledged that it does not have the statutory authority to mandate disclosures about product prices under the Food, Drug, and Cosmetic Act (the Act). The plaintiffs also point out that the FDA has previously determined that even truthful price disclosures in drug ads may create an unbalanced net impression of the product, which would in turn make the ad misleading and in violation of the Act and the agency's prescription drug advertising regulations.

Not finding the ideal response from FDA, the plaintiffs note, HHS turned towards the Centers for Medicare and Medicaid Services (CMS) and its primary governing statute, the Social Security Act. CMS explained in the final rule that it had authority to promulgate the WAC disclosure requirement because direct-to-consumer pharmaceutical television advertisements contain pricing information that "has a clear nexus to the Social Security Act" and the Medicare and Medicaid programs administered by CMS. HHS argued that consumer advertisements will ultimately save the Medicare and Medicaid programs money by driving down the list price of medications. However, the Complaint counters that the WAC disclosure requirement may have the opposite effect – such advertisements may discourage patients from receiving beneficial treatments and, in turn, may actually "increase the total cost of care." At the end of the day, it is unclear whether these consumer advertisements would save the Medicare and Medicaid programs any money.

First Amendment

The plaintiffs' second argument also is simple in its construction; they allege that the final rule violates the First Amendment. Generally, when the government compels commercial speech to convey the government's preferred messages, it bears a heavy evidentiary burden of showing "at a minimum, that the speech mandate will directly and materially advance a substantial government interest that could not be satisfied through other means."

According to the Complaint, HHS has conceded that it lacks any proof that compelling these WAC disclosure statements will advance its stated goals of reducing costs for Medicare and Medicaid and has conceded that it lacks the data necessary to evaluate what effects the final rule could actually have on the total cost of care in those government health care programs. An implied message of the plaintiffs to the District Court also appears to be that the government's true reasons for promulgating the final rule are political in nature and therefore cannot meet the constitutional burdens for compelled speech under the First Amendment.

HHS' Response to the Lawsuit

Following the plaintiffs' initiation of the lawsuit, HHS spokesperson Caitlin Oakley said, "If the drug companies are embarrassed by their prices or afraid that the prices will scare patients away, they should lower them." She added that "President Trump and [HHS] Secretary [Alex] Azar are committed to providing patients the information they need to make their own informed health care decisions."

Going Forward

The lawsuit itself is wholly unsurprising. The pharmaceutical industry has criticized the WAC disclosure requirement since it was first proposed in 2018. As the plaintiffs caution in their Complaint, "far from promoting transparency and improved decision-making . . . the rule would instead force pharmaceutical companies to mislead tens of millions of Americans about the price they would actually pay for important medicines that might improve their health or even save their lives." What's more, the plaintiffs allege that HHS is counting on patients to believe those high list prices apply to them and to subsequently forego care in hopes of creating cost savings that may eventually be passed on to patients. As such, they argue, the final rule is flawed and should not be allowed to go into effect as scheduled on July 9, 2019.

However, at the same time, how the District Court weighs the various interests in this case and whether the political firestorm that is high drug prices could affect the court's willingness to vacate the final rule is harder to predict. There will definitely be a lot more to come in this case, so stay tuned for further updates!

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions